EP Patent

EP4676462A1 — Therapy for bladder cancer

Assigned to Photocure ASA · Expires 2026-01-14 · 0y expired

What this patent protects

The present invention relates to the treatment of bladder cancer. In particular, it relates to a composition comprising hexyl 5-ALA ester (HAL), or a pharmaceutically acceptable salt thereof, for use in a method of therapy for bladder cancer, wherein said method comprises instill…

USPTO Abstract

The present invention relates to the treatment of bladder cancer. In particular, it relates to a composition comprising hexyl 5-ALA ester (HAL), or a pharmaceutically acceptable salt thereof, for use in a method of therapy for bladder cancer, wherein said method comprises instillation of said composition into the bladder of a patient, and wherein said method is not a method of photodynamic therapy.

Drugs covered by this patent

Patent Metadata

Patent number
EP4676462A1
Jurisdiction
EP
Classification
—
Expires
2026-01-14
Drug substance claim
No
Drug product claim
No
Assignee
Photocure ASA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.